START WITH YOUR QUESTION

Explore the evidence by outcome

Find what has been assessed, who or what was studied, and the limits of the finding.

This finder uses the same selected-source assessments as the peptide and stack guides. Evidence types describe the underlying source research, which may be indirect for the requested outcome. Filters select existing assessments; they do not recalculate grades or establish treatment recommendations. Topics without an outcome assessment remain in the peptide directory.

Clear all filters

32 assessments match these filters. Showing 20 on page 1 of 2.

Select two assessments below. This compares their scope, not treatment effectiveness.

Collagen peptides · Peptide assessment

Activity-related joint pain

Human research

Population / model
147 athletes recruited; 97 analyzed
Formulation / route
Oral collagen hydrolysate
Study design
Randomized double-blind placebo-controlled trial

Oral collagen hydrolysate may improve some measures of activity-related joint discomfort, but the evidence is less decisive than marketing often suggests.[1] A 24-week randomized trial recruited 147 athletes and analyzed 97; several pain measures favored collagen over placebo.[1] The missing participants, multiple outcomes, and specific athletic population limit confidence and generalizability.[1]

Main limitation: Attrition, multiple outcomes, and limited population applicability.[1]

LowRead the complete assessment

BPC-157 · Peptide assessment

Added benefit of a peptide combination

Human and preclinical research

Population / model
4 human combination recipients; rats with repaired Achilles tendons
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Small nonrandom human subgroup and randomized exploratory rat study

The knee case series included only four recipients of BPC-157 plus thymosin beta-4 and did not randomize treatment.[2] A rat Achilles study found no additional benefit from its BPC-157/TB-500 combination over monotherapy, with small endpoint samples.[3] Neither study establishes the benefit or safety of commercial peptide blends in people.[2][3]

Main limitation: Formulation and route cannot be generalized.[2][3]

Very lowRead the complete assessment

GLOW stack · Stack assessment

Additional recovery benefit from GHK-Cu

Animal or cell research

Population / model
Rats after Achilles tendon surgery
Formulation / route
BPC-157 / TB-500; no GHK-Cu group
Study design
Indirect animal combination research

The experiment did not test the three-component combination.[3]

Main limitation: A missing treatment group cannot establish an added effect.[3]

LowRead the complete assessment

Wolverine stack · Stack assessment

Additional tendon-healing benefit

Animal or cell research

Population / model
32 rats; four tendons per group for each endpoint type
Formulation / route
Experimental BPC-157 / TB-500 combination
Study design
Controlled rat experiment

No additional benefit was demonstrated for the combination in this model.[3]

Main limitation: An early surgical rat model cannot establish clinical recovery in people.[3]

LowRead the complete assessment

Wolverine stack · Stack assessment

Better knee-pain relief from the combination

Human research

Population / model
Four combination recipients within a knee-pain case series
Formulation / route
Intra-articular BPC-157 with thymosin beta-4
Study design
Uncontrolled human case series

The small, nonrandomized subgroup cannot establish an added treatment effect.[2]

Main limitation: The studied preparation cannot be assumed equivalent to a commercial TB-500 blend.[2]

LowRead the complete assessment

BPC-157 · Peptide assessment

Circulating growth hormone in humans

Animal or cell research

Population / model
Cultured rat tendon fibroblasts
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Controlled in vitro receptor-expression experiment

A cell-culture study found increased growth-hormone receptor expression in rat tendon fibroblasts.[4] That is different from demonstrating increased circulating growth hormone, and it does not validate combining BPC-157 with growth-hormone secretagogues in people.[4] Receptors describe how a cell may respond to a hormone; this experiment did not measure a rise in blood growth-hormone levels or test a clinical benefit from raising those levels.[4]

Main limitation: Receptor expression is not systemic hormone concentration.[4]

No direct human evidenceRead the complete assessment

Tirzepatide · Peptide assessment

Comparative weight reduction over 72 weeks

Human research

Population / model
751 adults with obesity without diabetes
Formulation / route
Subcutaneous trial formulations and maximum tolerated regimens
Study design
Open-label randomized head-to-head trial

In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight reduction than semaglutide in adults with obesity without diabetes.[5] Among 751 randomized participants, mean weight change at 72 weeks was −20.2% with tirzepatide and −13.7% with semaglutide, using the maximum tolerated trial regimens.[5] The trial was open-label and manufacturer funded, which should be considered alongside its direct randomized comparison.[5]

Main limitation: Open-label, manufacturer-funded, specific regimens and population.[5]

ModerateRead the complete assessment

BPC-157 · Peptide assessment

Human digestive benefit

Animal or cell research

Population / model
Rat gastric-injury models; separate human ulcerative-colitis abstract
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Rat injury experiments; regulatory assessment of an abstract-only human trial

Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[6][7] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[8] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[6][8]

Main limitation: Human evidence includes an incompletely reported meeting abstract, with insufficient detail to assess effectiveness reliably.[6][7][8]

Very lowRead the complete assessment

KLOW stack · Stack assessment

Human intestinal benefit from KLOW

Animal or cell research

Population / model
Intestinal / immune cells and mice with experimental colitis
Formulation / route
KPV alone; oral administration in mice
Study design
Indirect cell and animal experiments

The study does not test the KLOW combination in humans.[9]

Main limitation: Experimental inflammatory outcomes are not established clinical benefits of a four-peptide blend.[9]

LowRead the complete assessment

BPC-157 · Peptide assessment

Human pharmacokinetics

Human and preclinical research

Population / model
Rats and dogs;2human safety participants
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Animal LC-MS/MS pharmacokinetics; human safety pilot without PK assays

The pharmacokinetic paper reported mean intact-peptide half-lives below thirty minutes in tested rat and dog regimens.[10] The two-person human intravenous paper measured clinical laboratory markers rather than BPC-157 concentrations.[11] These studies therefore do not establish a human half-life or dosing frequency.[10][11]

Main limitation: Intact peptide must be distinguished from total radiolabel.[10][11]

No direct human evidenceRead the complete assessment

BPC-157 · Peptide assessment

Human safety

Human research

Population / model
Two previously exposed adults; broader clinical-note cohort
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Two-person safety pilot; uncontrolled EHR preprint

The two-person intravenous pilot reported no adverse effects during three days of monitoring, but both participants had previous exposure.[11] This small, selected sample cannot establish routine or long-term safety.[11] The clinical-note preprint also describes neuropsychiatric, skin or injection-site, and gastrointestinal symptoms, without establishing causation or reliable event rates.[12]

Main limitation: Brief monitoring and nonstandard adverse-event ascertainment.[11][12]

Very lowRead the complete assessment

GHK-Cu · Peptide assessment

Injected versus topical skin benefit

Evidence type not classified

Population / model
No matched human comparison identified
Formulation / route
Systemic injection versus topical application
Study design
No direct comparative human study identified

Clinical superiority of injected GHK-Cu over topical GHK-Cu has not been demonstrated in the human evidence reviewed here.[13][14] A topical study cannot establish the effectiveness or safety of systemic injection, because exposure and delivery are different.[13] FDA identifies limited human safety data for injectable GHK-Cu and potential immunogenicity associated with aggregation and peptide impurities.[14]

Main limitation: A delivery hypothesis does not establish benefit or safety.[13][14]

No direct human evidenceRead the complete assessment

TB-500 · Peptide assessment

Injury healing with the TB-500 fragment

Evidence type not classified

Population / model
Ophthalmic trials do not represent musculoskeletal-injury treatment
Formulation / route
Marketed injectable fragment versus researched ophthalmic full-length peptide
Study design
No direct human fragment evidence; indirect full-length ophthalmic trial

The name TB-500 requires clarification before interpreting any study.[14] FDA describes TB-500 as the thymosin beta-4 fragment LKKTETQ and reports that it has not identified human exposure data for that fragment.[14] Full-length thymosin beta-4 has been studied in humans, including investigational eye drops for corneal disease, but that is a different molecule, formulation, target tissue, and route.[15]

Main limitation: Molecular identity and route prevent extrapolation.[14][15]

No direct human evidenceRead the complete assessment

BPC-157 · Peptide assessment

Interstitial-cystitis symptoms

Human research

Population / model
12 women with interstitial cystitis
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Uncontrolled retrospective case series

An uncontrolled retrospective report described twelve women treated by cystoscopic bladder injection; ten reported complete symptom resolution and two partial improvement.[16] The paper describes follow-up timing inconsistently, and the lack of a comparator prevents attributing improvement to BPC-157.[16] This procedure-specific report does not establish that oral or subcutaneous products treat bladder pain.[16]

Main limitation: No comparator; inconsistent timing; route-specific procedure.[16]

Very lowRead the complete assessment

BPC-157 · Peptide assessment

Knee-pain symptom relief

Human research

Population / model
16 contacted patients,12 receiving BPC-157 alone
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Uncontrolled retrospective case series

Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[2] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[2] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[2]

Main limitation: No placebo or objective repair endpoint.[2]

Very lowRead the complete assessment

CJC-1295 + ipamorelin · Stack assessment

Long-term safety of the combination

Context sources

Population / model
Limited clinical safety information
Formulation / route
CJC-1295 and ipamorelin products
Study design
Regulatory safety assessment

Available safety information does not validate long-term use of the combination.[14]

Main limitation: Regulatory concerns cannot be converted into a reliable event rate for the pair.[14]

LowRead the complete assessment

BPC-157 · Peptide assessment

Muscle recovery in people

Animal or cell research

Population / model
Rats with induced muscle injuries
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Controlled rat surgical and crush-injury experiments

Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[17][18] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[19] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[17][18][19]

Main limitation: No direct human muscle-recovery trial in these studies.[17][18][19]

No direct human evidenceRead the complete assessment

BPC-157 · Peptide assessment

Oral versus injected effectiveness

Animal or cell research

Population / model
Rats and dogs
Formulation / route
Study-specific; no cross-route equivalence assumed
Study design
Animal route-specific experiments; no human head-to-head comparison in these sources

Oral administration produced effects in some rat injury experiments, but those experiments did not measure clinical equivalence in humans.[6][17] A pharmacokinetic study examined intravenous and intramuscular administration in rats and dogs; it did not evaluate human oral absorption.[10] These sources do not establish that capsules and injections are interchangeable.[10][17]

Main limitation: Animal responses are not human bioavailability.[6][10][17]

No direct human evidenceRead the complete assessment

Semaglutide · Peptide assessment

Quality assurance of no-prescription online products

Product-testing research

Population / model
Three delivered products from six selected online orders
Formulation / route
Products sold for injection
Study design
Small observational test-purchase and laboratory study

A purity percentage does not establish correct identity, labeled amount, sterility, endotoxin control, or clinical safety.[20] In a 2024 test-purchase study of no-prescription online semaglutide, only three of six orders arrived.[20] The delivered samples contained more semaglutide than labeled, had reported purity far below the advertised 99%, and one contained elevated endotoxin despite no viable microorganisms being detected.[20]

Main limitation: Documents failures; does not estimate market-wide prevalence.[20]

LowRead the complete assessment

CJC-1295 · Peptide assessment

Recovery or muscle-performance benefit

Human research

Population / model
Healthy adults followed for 28 or 49 days
Formulation / route
Subcutaneous long-acting CJC-1295 in the cited trials
Study design
Randomized pharmacology trials; indirect for clinical benefit

CJC-1295 has demonstrated hormonal activity in humans, but that does not establish improved recovery or muscle performance.[21] Two short randomized, placebo-controlled trials of the long-acting formulation found increases in growth hormone and IGF-1 in healthy adults.[21] These were pharmacology studies, not demonstrations of faster injury healing, greater strength, better sleep, or longer life.[21]

Main limitation: GH and IGF-1 are surrogate outcomes for the proposed benefits.[21]

No direct human evidenceRead the complete assessment

How certainty is assessed · Study reviews and review coverage